Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Mycenax Biotech Inc.

Home Clinical Trial Sponsors and OrganizationsMycenax Biotech Inc.

Mycenax Biotech Inc.

7F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu, Taiwan

Also known as:

mycenax

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

5

1 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

3

60.0%

Phase 1

2

40.0%

Trial Status Distribution

Active, not recruiting

1

20.0%

Completed

1

20.0%

Terminated

1

20.0%

Unknown

2

40.0%

Clinical Trials

Trials sponsored by this organization (5)

Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)

Active, not recruiting

May 2018190 participants

Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers

Oct 2017190 participants

A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis

Sep 201610 participants

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis

Sep 201398 participants

A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA

Nov 201291 participants

Approvals

No approval data available

News

Mycenax Biotech and SPERA PHARMA Form Strategic Alliance to Enhance ADC Manufacturing Capabilities

- Mycenax Biotech Inc., a Taiwan-based biologics CDMO, has announced a strategic alliance with Japan's SPERA PHARMA Inc. to enhance antibody-drug conjugate manufacturing services. - The partnership combines Mycenax's expertise in biologics development and manufacturing with SPERA PHARMA's capabilities in pharmaceutical chemistry, manufacturing, and controls processes. - The collaboration aims to optimize workflows and improve efficiency in ADC drug substance and drug product manufacturing to address growing market demand. - Both companies seek to leverage their respective strengths to maintain high-quality standards while streamlining ADC manufacturing workflows for biopharmaceutical clients.

On this page

Overview
Clinical Trials5
Approvals
News1

Back to Organizations